Chondrofix Osteochondral Allograft Prospective Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01410136
Recruitment Status : Terminated (Inadequate enrollment and decreased need for clinical data to support product)
First Posted : August 4, 2011
Last Update Posted : August 11, 2014
Information provided by (Responsible Party):
Zimmer Orthobiologics, Inc.

August 2, 2011
August 4, 2011
August 11, 2014
April 2011
March 2014   (Final data collection date for primary outcome measure)
KOOS Subscale [ Time Frame: 24 Months ]
The overall mean change from baseline to 24 months in the KOOS Pain and KOOS Function in Daily Living (ADL) subscale scores.
Same as current
Complete list of historical versions of study NCT01410136 on Archive Site
  • X-ray & MRI Evaluation [ Time Frame: Baseline and 1.5, 3, 6, 12, 24, & 60 months ]
  • IKDC Knee Examination [ Time Frame: Baseline & 1.5, 3, 6, 12, 24, & 60 months ]
  • Subject Reported Questionnaires [ Time Frame: Baseline and 1.5, 3, 6, 12, 24, 36, 48, and 60 months ]
Same as current
Not Provided
Not Provided
Chondrofix Osteochondral Allograft Prospective Study
A Post Market Study to Evaluate the Chondrofix® Osteochondral Allograft Utilized for Treatment of Subjects With Cartilage Lesions in the Knee
The overall study objective is to evaluate Chondrofix Osteochondral Allograft ("Chondrofix") for the repair of osteochondral lesions in the knee. This includes, but is not limited to primary cartilage lesion repair and revision of failed prior cartilage repair treatments. The study hypothesis is that Chondrofix Allograft will provide pain relief and functional improvement as demonstrated by a comparative analysis of baseline clinical evaluations at 24 months of follow-up.

Knee cartilage injuries are a major cause of pain and functional impairment in young to middle age adults and can lead to progressive joint degeneration. In response to challenges with current cartilage repair options, Chondrofix Allograft was developed as an off-the-shelf treatment option adding to the variety of cartilage reparation offerings.

This study is a multicenter, prospective, post-market clinical outcomes study designed to assess the clinical outcomes of Chondrofix Allograft used in the treatment of both primary and revision cartilage repair cases. Study design includes up to 6 qualified investigational sites with 50 subjects enrolled across all centers during an 18 month enrollment period. Study subjects will be followed postoperatively for 5 years. The Investigators who are responsible for the conduct of this study in compliance with this protocol will be orthopedic surgeons who are skilled in the techniques of articular cartilage repair.

Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Articular Cartilage Disorder
  • Degeneration; Articular Cartilage
  • Chronic Cartilage Injury
  • Acute Cartilage Injury
  • Defect of Articular Cartilage
Procedure: Chondrofix Osteochondral Allograft
Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
Other Name: Chondrofix
Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
Intervention: Procedure: Chondrofix Osteochondral Allograft
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2014
March 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Generally, the following inclusion criteria must be met, however, this is not a complete list.

  • Male and non-pregnant female subjects between 18 and 70 years; subject must be skeletally mature
  • If female, subjects are not pregnant at time of surgery and do not plan on becoming pregnant during the first 24 months of the study
  • Up to two (2) cartilage lesion(s), each measuring less than 8 cm2, of the femoral condyle or trochlear groove of the knee
  • Localized knee pain unresponsive to conservative treatment (e.g., medication, bracing, physical therapy) and/or previous surgical intervention

Exclusion Criteria:

Generally, if a potential participant meets any of the following criteria, they will not be eligible for this study. Additionally, more criteria will be evaluated to confirm eligibility as this list is not a complete list of criteria.

  • Concurrent participation in another clinical trial
  • Cartilage lesion location is such that the implanted graft(s) will not be adequately shouldered
  • Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface)
  • Is receiving pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition
  • Subject had any other cartilage repair procedure other than debridement performed in conjunction with or 6 months prior to implantation of a Chondrofix Osteochondral Allograft
  • Prior or concurrent total meniscectomy of the index knee
  • Uncorrected mal-alignment of the index knee
  • Have smoked or used nicotine products within the past 6 months
  • Body Mass Index > 35 (BMI=kg/m2)
  • Has any contraindications for MRI
  • Requires any of the following concomitant procedures performed in conjunction with or has had performed within 6 months prior to implantation of a Chondrofix Allograft: distal realignment, high tibial osteotomy, ligament reconstruction, and/or patellar realignment procedure
  • Septic or reactive arthritis or systemic disease (e.g., rheumatoid arthritis, gout or prior history of gout or pseudo gout)
  • Sickle cell disease, hemochromatosis, or autoimmune disease
  • Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes
  • HIV or other immune-deficient state including subject on immunosuppressant therapies
  • Deficiency limiting ability to perform an objective functional assessment of the operative knee or an inability to adhere to a post-operative rehabilitation protocol
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Zimmer Orthobiologics, Inc.
Zimmer Orthobiologics, Inc.
Not Provided
Study Chair: Nikesha N Harrington Zimmer Orthobiologics, Inc.
Zimmer Orthobiologics, Inc.
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP